Viridian Therapeutics, Inc. (NASDAQ:VRDN) CEO Scott Dunseth Myers Buys 5,500 Shares of Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) CEO Scott Dunseth Myers bought 5,500 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, March 13th. The stock was purchased at an average price of $29.15 per share, with a total value of $160,325.00. Following the purchase, the chief executive officer now directly owns 255,500 shares in the company, valued at $7,447,825. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Viridian Therapeutics Stock Performance

NASDAQ VRDN opened at $28.85 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.93 and a quick ratio of 12.93. Viridian Therapeutics, Inc. has a 1 year low of $9.47 and a 1 year high of $39.00. The company has a market capitalization of $821.07 million, a PE ratio of -7.16 and a beta of 0.95. The company has a fifty day moving average of $33.71 and a two-hundred day moving average of $26.64.

Viridian Therapeutics (NASDAQ:VRDN – Get Rating) last posted its quarterly earnings results on Wednesday, March 8th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.41). The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.46 million. Viridian Therapeutics had a negative return on equity of 84.78% and a negative net margin of 7,329.23%. The company’s revenue for the quarter was down 50.9% on a year-over-year basis. During the same period in the prior year, the company earned ($1.32) earnings per share. As a group, analysts expect that Viridian Therapeutics, Inc. will post -4.08 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Metropolitan Life Insurance Co NY boosted its position in Viridian Therapeutics by 47.0% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 2,340 shares of the company’s stock worth $68,000 after acquiring an additional 748 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at $77,000. Silverarc Capital Management LLC purchased a new stake in shares of Viridian Therapeutics during the 4th quarter valued at $88,000. Legal & General Group Plc purchased a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at $94,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at $128,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. LADENBURG THALM/SH SH restated a “buy” rating and issued a $40.00 target price on shares of Viridian Therapeutics in a research note on Thursday, March 9th. Credit Suisse Group began coverage on Viridian Therapeutics in a research note on Friday, December 16th. They set an “outperform” rating and a $51.00 price objective for the company. SVB Leerink lifted their price objective on Viridian Therapeutics from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, January 9th. Cowen began coverage on Viridian Therapeutics in a research note on Monday, December 19th. They set an “outperform” rating for the company. Finally, B. Riley lifted their price objective on Viridian Therapeutics from $40.00 to $46.00 in a research note on Tuesday, January 10th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Viridian Therapeutics presently has an average rating of “Buy” and an average target price of $45.10.

About Viridian Therapeutics

(Get Rating)

Viridian Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis.